<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report here a retrospective analysis of 36 children with therapy-related <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) diagnosed between 1990 and 1999 in Japan </plain></SENT>
<SENT sid="1" pm="."><plain>Their median age was 7.7 years and the median latency period for the development of t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> was 38.5 months </plain></SENT>
<SENT sid="2" pm="."><plain>The <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> were hematologic in 15 of the cases and nonhematologic in 21 </plain></SENT>
<SENT sid="3" pm="."><plain>Chromosomal abnormalities were detected in 32/34(94%) patients: abnormalities of chromosomes 5and/or 7 in 41% and notably, 11q23 abnormalities in 31% </plain></SENT>
<SENT sid="4" pm="."><plain>The prognosis of children with t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> was very poor as compared to children with primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (5 year survival: 16% versus 54%, p&lt;0.0001) </plain></SENT>
</text></document>